Device Trial Radar · NCT06788977
External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Nov 25, 2024
Primary completion
Apr 2027
Study completion Dec 2030
Sponsor
- Lead sponsor
- Cefaly TechnologyNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 23, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 44 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women. Women do not need to use external trigeminal nerve stimulation or any other form of migraine treatment to participate in the registry. The main question it aims to answer is: Is external trigeminal nerve stimulation a safe and effective option for migraine treatment during and after pregnancy? There are no required changes in migraine treatment to participate in this registry. Participants may or may not use external trigeminal nerve stimulation or any other treatment they currently use and may still participate in the registry. There are no clinic or research visits, as the registry is entirely online. Participants will be asked to complete up to six 15- 20-minute surveys over a time period of up to 12 months.
Conditions
- Pregnancy
- Migraine
- Headache
- Postpartum
- Depression
- Anxiety
Interventions
external Trigeminal Nerve StimulationDevice
External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine. The CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of miscarriage per trimesterTime frame: through study completion average 2 years
- Postpartum Bonding according to the Maternal-to-Infant Bonding ScaleTime frame: through study completion average 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
https://public.smart-trial.co/#/public/649d77f0e8f8d0fb993d0c61/6626f6a04f0a3c7dd0860e14/662726d84f0a3c7dd08aeaa0/signup?lang=en-us&enforceLanguage=true
Darien, Connecticut · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.